首页> 外文期刊>Genetic testing and molecular biomarkers >Fibroblast Growth Factor Receptor 4 Polymorphisms Are Associated with Coronary Artery Disease
【24h】

Fibroblast Growth Factor Receptor 4 Polymorphisms Are Associated with Coronary Artery Disease

机译:成纤维细胞生长因子受体4多态性与冠状动脉疾病相关。

获取原文
获取原文并翻译 | 示例
       

摘要

Fibroblast growth factor receptor 4 (FGFR4) plays crucial roles in vascular smooth muscle cell proliferation and atherosclerosis and, therefore, may potentially affect the development of coronary artery disease (CAD). The aim of this study was to investigate the association between FGFR4 polymorphisms and the susceptibility to CAD in the Chinese population. Two polymorphisms, rs192201146G/A (Asp756Asn) and rs188755817C/G (Ser778Arg), were detected by polymerase chain reaction-restriction fragment length polymorphism and direct sequencing in 722 CAD cases and 802 age-matched controls. Data were analyzed using the chi-square test. Results showed that frequencies of rs192201146GA genotype and rsl88755817CG genotype were significantly higher in CAD patients than in controls (odds ratio [OR] = 1.92, 95% confidence interval [CI] 1.11-3.28, p = 0.016, and OR=1.87, 95% CI 1.06-3.30, p = 0.027). Similarly, numbers of the rs192201146A allele and the rs188755817G allele were significantly increased in CAD cases (OR=1.89, 95% CI 1.11-3.22, p = 0.017, and OR=1.85, 95% CI 1.06-3.24, p = 0.029). Haplotype analysis revealed that GG and AC (rs192201146 rs188755817) haplotypes had higher frequencies in CAD patients (OR=2.75, p = 0.002 and OR=2.69, p=0.001). Our data suggested that the FGFR4 rs192201146 (Asp756Asn) and rs188755817 (Ser778Arg) polymorphisms could act as risk factors for CAD in the Chinese population.
机译:成纤维细胞生长因子受体4(FGFR4)在血管平滑肌细胞增殖和动脉粥样硬化中起关键作用,因此可能潜在地影响冠状动脉疾病(CAD)的发展。这项研究的目的是调查中国人群中FGFR4多态性与CAD易感性之间的关系。通过聚合酶链反应-限制性片段长度多态性和直接测序法在722例CAD患者和802个年龄匹配的对照中检测到两个多态性rs192201146G / A(Asp756Asn)和rs188755817C / G(Ser778Arg)。使用卡方检验分析数据。结果显示,CAD患者中rs192201146GA基因型和rsl88755817CG基因型的频率显着高于对照组(比值[OR] = 1.92,95%置信区间[CI] 1.11-3.28,p = 0.016,OR = 1.87,95% CI 1.06-3.30,p = 0.027)。类似地,在CAD病例中rs192201146A等位基因和rs188755817G等位基因的数目显着增加(OR = 1.89,95%CI 1.11-3.22,p = 0.017,OR = 1.85,95%CI 1.06-3.24,p = 0.029)。单倍型分析显示,GG和AC(rs192201146 rs188755817)单倍型在CAD患者中具有更高的频率(OR = 2.75,p = 0.002和OR = 2.69,p = 0.001)。我们的数据表明,FGFR4 rs192201146(Asp756Asn)和rs188755817(Ser778Arg)多态性可能是中国人群CAD的危险因素。

著录项

  • 来源
    《Genetic testing and molecular biomarkers》 |2012年第8期|p.952-956|共5页
  • 作者单位

    Cardiac Pacing and Electrophysiology Lab, Cardiology Division, Beijing Hospital, Ministry of Health, Beijing, China,Cardiology Division, Anzhen Hospital, Capital Medical University, Beijing, China;

    Cardiac Pacing and Electrophysiology Lab, Cardiology Division, Beijing Hospital, Ministry of Health, Beijing, China;

    Cardiac Pacing and Electrophysiology Lab, Cardiology Division, Beijing Hospital, Ministry of Health, Beijing, China;

    Cardiac Pacing and Electrophysiology Lab, Cardiology Division, Beijing Hospital, Ministry of Health, Beijing, China;

    Cardiac Pacing and Electrophysiology Lab, Cardiology Division, Beijing Hospital, Ministry of Health, Beijing, China;

    Cardiology Division, Anzhen Hospital, Capital Medical University, Beijing, China;

    Cardiac Pacing and Electrophysiology Lab, Cardiology Division, Beijing Hospital, Ministry of Health, Beijing, China;

    Cardiology Division Anzhen Hospital Capital Medical University No. 2 Anzhen Road Beijing 100029 China;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 13:18:52

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号